Clinical Trial Update: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) [Phase 3]

View source ↗

Summary

COMBINE 2 is a Phase 3 study comparing the weekly combo therapy IcoSema (insulin icodec plus semaglutide) to weekly semaglutide in adults with type 2 diabetes; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IcoSema (insulin icodec and semaglutide)
• Insulin Icodec (insulin icodec)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2025-01-17